Back to Search
ERIC JONASCH, M.D.
M.D.
Medical Oncology Physician
NPI: 1558457028IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
L5394(TX)
CMS Specialties
PrimaryMEDICAL ONCOLOGY
Education
OTHER
Class of 1992
Research & Publications (20)
Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma.
PMID 19636008·J Clin Oncol·2009
3-trial
Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma.
PMID 18484647·Cancer·2008
3-trial
Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings.
PMID 18362942·Br J Cancer·2008
8-other
Presurgical therapy in metastatic renal cell carcinoma.
PMID 17187521·Expert Rev Anticancer Ther·2007
6-review
Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib.
PMID 19213663·Clin Genitourin Cancer·2009
8-other
NCCN clinical practice guidelines in oncology: testicular cancer.
PMID 19555582·J Natl Compr Canc Netw·2009
6-review
NCCN clinical practice guidelines in oncology: kidney cancer.
PMID 19555584·J Natl Compr Canc Netw·2009
6-review
Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma.
PMID 19402074·Cancer·2009
6-review
Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon: impact of therapy on recurrence patterns and outcome measures.
PMID 19241453·Cancer·2009
8-other
Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma.
PMID 18950837·Urology·2009
4-observational
Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma.
PMID 19118035·Clin Cancer Res·2009
8-other
Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-alpha: association of pretreatment serum levels with survival.
PMID 19541791·Ann Oncol·2009
8-other
Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors.
PMID 19017755·J Clin Endocrinol Metab·2009
5-case
Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma.
PMID 19338544·BJU Int·2009
8-other
Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.
PMID 18485389·J Urol·2008
8-other
A novel von Hippel-Lindau point mutation presents as apparently sporadic pheochromocytoma.
PMID 18584357·Cancer Invest·2008
5-case
A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents.
PMID 18635226·J Urol·2008
3-trial
Current status of debulking nephrectomy in the era of tyrosine kinase inhibitors.
PMID 18765156·Curr Oncol Rep·2008
6-review
Inhibition of Mxi1 suppresses HIF-2alpha-dependent renal cancer tumorigenesis.
PMID 19018165·Cancer Biol Ther·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1515 HOLCOMBE BLVD, 77030-4009
HOUSTON, TX 77030 - Phone
- (713) 792-6161
Quick Facts
- NPI
- 1558457028
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 34
- Publications
- 20
Are you this provider?
Claim Your Profile